Bicara Therapeutics Inc BCAX
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2024-09-13 |
| Shares Out. | 65,700,000 |
| Website | bicara.com/ ↗ |
| Phone | 16174684219 |
| Employees | 103 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$55.4M |
| Free Cash Flow | -$135.2M |
| Total Assets | $512.2M |
| Total Liabilities | $43.5M |
| Equity | $468.8M |
About Bicara Therapeutics Inc
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. The company's goal is to build a fully integrated, commercial-stage biopharmaceutical company that develops important therapies for people living with cancer, starting with ficerafusp alfa.
Bicara Therapeutics Inc is a publicly traded company under the ticker symbol BCAX on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
22 analysts (2026-09-01)